CVS

Cigna, Express, and the Unwinding of the PBM Market

by

Given its track record of creative destruction, when Amazon plans to enter a particular line of business, it presents an ominous threat to incumbents. What is often overlooked, too, is that Amazon is more than willing to try new verticals—if they prove promising, additional assets will be devoted to the new line of business, often with fawning media coverage. If Amazon is unsuccessful in its endeavor, however, then it seems as though it will “fail fast” and shut down the project and move on. We found the recent announcement of a joint venture to tackle the healthcare industry as particularly noteworthy. By Alexander J. Poulos Amazon as the Great Disrupter We have marveled at Amazon’s (AMZN) rumored ambition into pharmaceutical … Read more

The “Luck” and “Randomness” of Index Funds

by

Please select the image below to download the document. Image shown, page 1 of 14. Tickerized for Valuentum’s coverage universe.

Rising Risk Free Rates Threatening Market, Removing CVS and Hanesbrands

by

The most important variable to keep your eye on, the 10-year Treasury, is rising, and the long-term implications on equity values could be considerable. We don’t think the moves thus far have been too disruptive, but continued concerns over US tax receipts and infrastructure/defense spending could send sovereign yields roaring higher. As fourth-quarter earnings season marches on, let’s take a look at some meaningful recent quarterly reports. We’re also shedding two companies from the simulated newsletter portfolios. By Kris Rosemann and Brian Nelson, CFA The market continues to be on edge as it considers what the borrowing cost of US debt might be in the event of the next downturn, the timing the only uncertainty, now that it has significantly … Read more

Boeing!

by

Image shown: Boeing’s shares have been rocketing higher of late!  We couldn’t be more pleased with how one of our best ideas for consideration has performed: Boeing! By Kris Rosemann Dividend Gowth Newsletter portfolio idea Boeing (BA) continues its tremendous share-price run of late, hitting all-time highs following its earnings report before market open January 31. The aerospace giant turned in 9% revenue growth on a year-over-year basis, while GAAP earnings per share doubled from the year-ago period to $5.18. Free cash flow remained robust in the full-year 2017, advancing to ~$11.6 billion from ~$7.9 billion in 2016. The company expects operating cash flow to climb to ~$15 billion in 2018 (up from $13.3 billion in 2017), and its revenue … Read more

Video: Quants! You’re NOT Measuring VALUE and Nelson’s Theory of Universal Value

by

President of Investment Research Brian Nelson defines the concept of universal value and shows how quantitative statistical methods are inextricably linked to those of fundamental, financial, business-model related analysis. Value does not exist in respective process vacuums! Value is universal. Find out why. Running time: ~10 minutes.  Tickerized for Valuentum’s stock and ETF coverage universe. Transcript Hi this is Brian Nelson from Valuentum Securities, and this is the tenth edition of a series that I call “Off the Cuff,” where I get in front of the camera and I talk for ten minutes. This is what we have to talk about today. We have to talk about this concept: The Theory of Universal Value. Value does not exist in vacuums … Read more

Strategy Versus Tactics in the Dividend Growth Newsletter Portfolio

by

Image Source: fauxto_digit We made a few tactical tweaks to the Dividend Growth Newsletter portfolio during 2017. Let’s walk through them, and how we’re out to win the war, not win every battle. < Note: The introduction is the same as that of the tactical analysis of the Best Ideas Newsletter portfolio. If you have already read through the introduction, please proceed to the section, Dividend Growth Newsletter Portfolio below. > By Brian Nelson, CFA I’m not going to reference The Art of War written by Chinese military strategist Sun Tzu some time in the 5th century, nor am I going to use any quotes from the military treatise (I think it’s too well-traveled of a topic), but I do … Read more

Strategy Versus Tactics in the Best Ideas Newsletter Portfolio

by

Image Source: Anna & Michal We made a few tactical tweaks to the Best Ideas Newsletter portfolio during 2017. Let’s walk through them, and how we’re out to win the war, not win every battle. By Brian Nelson, CFA I’m not going to reference The Art of War written by Chinese military strategist Sun Tzu some time in the 5th century, nor am I going to use any quotes from the military treatise (I think it’s too well-traveled of a topic), but I do believe the approach to portfolio management is much like that of a general on a path to win the war. Now, don’t get me confused: I’m not saying that portfolio management is actually like being in … Read more

How Have Our Best “Dividend Growth Ideas” Performed During 2017?

by

Read about the ideas in the Best Ideas Newsletter portfolio >> We wrote recently about how well the top-weighted ideas in the Best Ideas Newsletter portfolio have performed during 2017, but what about the top-weighted ideas in the other newsletter portfolio, the Dividend Growth Newsletter portfolio? How have they performed during 2017? Please tell us you know how well the top-weighted ideas have been performing. Key Takeaways: 1) “Excluding dividends, the SPDR S&P 500 Dividend ETF has advanced less than 9% this year. Meanwhile, excluding dividends, the two top-weighted ideas in the Dividend Growth Newsletter portfolio, Johnson & Johnson and Intel, are up ~20% and ~24%, respectively, more than double that of the SPDR S&P 500 Dividend ETF.”  2) “We’re viewing … Read more

CVS Health Under Review – Hit by a Storm of Negativity

by

Image Source: Mike Mozart We are putting the fair value estimate of CVS Health under review while we re-evaluate the competitive environment and reassess the company’s appetite for leverage, which could impact dividend health. Brian Nelson, CFA Boy has CVS Health (CVS) been hit by a storm of negativity in recent months. After we added it to the newsletter portfolios, the company has gotten caught up in a whirlwind of investor concern regarding Amazon’s (AMZN) probable entrance in the pharmacy market. We noted as much in our September 30 note, “Amazon Casts a Large Shadow Over the Pharmacy Market,” and we said that even we were “growing more and more cautious on shares,” as we pointed to Amazon’s potential acquisition … Read more